Clay Siegall’s Career History

If you or someone close to you has been a beneficiary of ADCETRIS, I know you must have done your own research on the drug. This is the first anti-body conjugates (ADCs) to be approved by the Food and Drug Administration body. It is a product of Settle genetics, a company co-founded by Clay Siegall in the year 1998.

Clay Siegall has worked for the company as its President, CEO and Chairman of the board of Directors. He decided to get on the partnership in order to improve the existing oncological tools. His desire was inspired by the death of his father. Clay Siegall had watched his father die slowly of cancer. The disease made his life miserable, but there were no advanced oncology tools to heal him. Therefore, he vowed that he would venture into this field and be instrumental in the advancement of this tools. Today, through Seattle Genetics, Clay Siegall has lived his dreams. The company focusses on helping patients in over 65 countries, where their drugs are approved.

The trained and award-winning scientist who has authored over 70 publications has also acquired over 20 patents talked to Ideamensch in a recent interview. He advised other entrepreneurs to interact with smart professionals within their industry. As for him, he has found it very profitable to partner with leaders and innovators within his industry.


Other than Settle Genetics, Clay Siegall works for a number of companies within the industry, benefiting them with his expertise of over 30 years. He seats on the board of directors of Washington Roundtable, Alder BioPharmaceuticals, and Ultragenyx Pharmaceutical.


In the past, he worked for National Cancer Institute, National Institutes of Health. He was with the company from the year 1988 to the year 1997. He also worked for Bristol-Myers Squibb Pharmaceutical Research Institute, staying with the company from the year 1991 to the year 1998. He quit both companies when he co-founded Seattle Genetics. By starting his own company, he saw an opportunity to be optimally utilize his potential in offering oncological advancements to help treat cancer.


Leave a Reply

Your email address will not be published. Required fields are marked *